The 2022 DTRA Annual Meeting (November 6-9) convened the leaders advancing the global adoption of decentralized research. Sessions focused on progress to stabilize decentralized research, including perspectives from global regulators as well as updates on scaling adoption within multiple leading biopharmaceutical companies.

We look forward to bringing our Membership together again November 5-8, 2023 at the Encore Boston.

2022 Highlights  

The DTRA Regulatory update session featuring perspectives from:

• Dr. Leonard Sacks - Office of Medical Policy, CDER, U.S. Food and Drug Administration
• Dr. Catherine Ela - Head of the Clinical Trials Department, Israel Ministry of Health
• Ditte Zerland Christensen - EU Project Manager, Danish Medicines Agency

Perspectives spanned expectations of guidance and harmonization, feedback on implementations to-date, and where regulators need more input from the DCT community.

Ronnie Sharpe joined us at the DTRA Annual Meeting reminded us that we're here on this earth to serve our fellow humans and challenge how we think about patients in clinical trials as a CF patient himself.

Pharma Spotlights  

Our Pharma Spotlight Presentations featured DTRA Members sharing their DCT Journeys. Erica Lawson from Otsuka joined us to share about their first fully virtual trial and the lessons learned along the way. 

Jeremy Price from Pfizer joined us on the Main Stage at DTRA 2022 to discuss the Pfizer Pledge of getting 60% remote trials across all therapeutic areas in 2022. 

Hassan Kadhim from Bristol Myers Squibb shared their journey to climb the DCT mountain and what we can anticipate coming next.

Kim Hawkins from Sanofi joined us on stage at DTRA 2022 to discuss how they are disrupting the clinical trials process through DCTs.

Registrants of the 2022 DTRA  Annual Meeting can review recorded sessions in the Meeting App now.

Stay Informed on the Latest DTRA News

Join our mailing list to receive updates on the latest DTRA news, events, and more.  Subscribe Now